272 related articles for article (PubMed ID: 8823323)
21. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma.
Friedberg JW; Neuberg D; Stone RM; Alyea E; Jallow H; LaCasce A; Mauch PM; Gribben JG; Ritz J; Nadler LM; Soiffer RJ; Freedman AS
J Clin Oncol; 1999 Oct; 17(10):3128-35. PubMed ID: 10506609
[TBL] [Abstract][Full Text] [Related]
22. Autologous bone marrow transplantation for low-grade non-Hodgkin's lymphoma: the European Bone Marrow Transplant Group experience. EBMT Working Party for Lymphoma.
Schouten HC; Colombat P; Verdonck LF; Gorin NC; Björkstrand B; Taghipour G; Goldstone AH
Ann Oncol; 1994; 5 Suppl 2():147-9. PubMed ID: 8204514
[TBL] [Abstract][Full Text] [Related]
23. Outcome of high-dose therapy and autologous transplantation in non-Hodgkin's lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest.
Sharp JG; Kessinger A; Mann S; Crouse DA; Armitage JO; Bierman P; Weisenburger DD
J Clin Oncol; 1996 Jan; 14(1):214-9. PubMed ID: 8558200
[TBL] [Abstract][Full Text] [Related]
24. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial.
Schouten HC; Qian W; Kvaloy S; Porcellini A; Hagberg H; Johnsen HE; Doorduijn JK; Sydes MR; Kvalheim G
J Clin Oncol; 2003 Nov; 21(21):3918-27. PubMed ID: 14517188
[TBL] [Abstract][Full Text] [Related]
25. The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups.
Prince HM; Imrie K; Crump M; Stewart AK; Girouard C; Colwill R; Brandwein J; Tsang RW; Scott JG; Sutton DM; Pantalony D; Carstairs K; Sutcliffe SB; Keating A
Br J Haematol; 1996 Mar; 92(4):880-9. PubMed ID: 8616081
[TBL] [Abstract][Full Text] [Related]
26. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma.
Mills W; Chopra R; McMillan A; Pearce R; Linch DC; Goldstone AH
J Clin Oncol; 1995 Mar; 13(3):588-95. PubMed ID: 7884420
[TBL] [Abstract][Full Text] [Related]
27. Natural killer cell regeneration after transplantation with mafosfamide purged autologous bone marrow.
Almici C; Manoni L; Carlo-Stella C; Garau D; Cottafavi L; Rizzoli V
Bone Marrow Transplant; 1995 Jul; 16(1):95-101. PubMed ID: 7581136
[TBL] [Abstract][Full Text] [Related]
28. 4-Hydroperoxycyclophosphamide purged autologous bone marrow transplantation in non-Hodgkin's lymphoma patients at high risk of bone marrow involvement.
Bird JM; Luger S; Mangan P; Edelstein M; Silberstein L; Powlis W; Ball J; Schultz DJ; Stadtmauer EA
Bone Marrow Transplant; 1996 Aug; 18(2):309-13. PubMed ID: 8864439
[TBL] [Abstract][Full Text] [Related]
29. 'Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma.
Chen CI; Roitman D; Tsang R; Stewart AK; Keating A; Crump M
Bone Marrow Transplant; 2002 Dec; 30(12):885-91. PubMed ID: 12476281
[TBL] [Abstract][Full Text] [Related]
30. High-dose therapy and autologous bone marrow transplantation in first complete remission for adult patients with high-grade non-Hodgkin's lymphoma: the EBMT experience. Lymphoma Working Party of the European Group for Bone Marrow Transplantation.
Sweetenham JW; Proctor SJ; Blaise D; De Laurenzi A; Pearce R; Taghipour G; Goldstone AH; Laurenzi A [corrected to De Laurenzi A]
Ann Oncol; 1994; 5 Suppl 2():155-9. PubMed ID: 7515646
[TBL] [Abstract][Full Text] [Related]
31. Autologous bone marrow transplantation in poor-prognosis intermediate-grade and high-grade B-cell non-Hodgkin's lymphoma in first remission: a pilot study.
Freedman AS; Takvorian T; Neuberg D; Mauch P; Rabinowe SN; Anderson KC; Soiffer RJ; Spector N; Grossbard M; Robertson MJ
J Clin Oncol; 1993 May; 11(5):931-6. PubMed ID: 8487057
[TBL] [Abstract][Full Text] [Related]
32. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
van Besien K; Margolin K; Champlin R; Forman S
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395
[TBL] [Abstract][Full Text] [Related]
33. Comparison of peripheral blood stem-cell and autologous bone marrow transplantation for lymphoma patients: a case-controlled analysis of the EBMT Registry data. Lymphoma Working Party of the EBMT.
Liberti G; Pearce R; Taghipour G; Majolino I; Goldstone AH
Ann Oncol; 1994; 5 Suppl 2():151-3. PubMed ID: 7911318
[TBL] [Abstract][Full Text] [Related]
34. Role of a second transplant in the management of poor-prognosis lymphomas: a report from the European Blood and Bone Marrow Registry.
Vandenberghe E; Pearce R; Taghipour G; Fouillard L; Goldstone AH
J Clin Oncol; 1997 Apr; 15(4):1595-600. PubMed ID: 9193358
[TBL] [Abstract][Full Text] [Related]
35. High-dose therapy and autologous bone marrow transplantation for intermediate and high grade non-Hodgkin's lymphoma in patients aged 55 years and over: results from the European Group for Bone Marrow Transplantation. The EBMT Lymphoma Working Party.
Sweetenham JW; Pearce R; Philip T; Proctor SJ; Mandelli F; Colombat P; Goldstone AH
Bone Marrow Transplant; 1994 Dec; 14(6):981-7. PubMed ID: 7711677
[TBL] [Abstract][Full Text] [Related]
36. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
Santini G; Salvagno L; Leoni P; Chisesi T; De Souza C; Sertoli MR; Rubagotti A; Congiu AM; Centurioni R; Olivieri A; Tedeschi L; Vespignani M; Nati S; Soracco M; Porcellini A; Contu A; Guarnaccia C; Pescosta N; Majolino I; Spriano M; Vimercati R; Rossi E; Zambaldi G; Mangoni L; Rizzoli V
J Clin Oncol; 1998 Aug; 16(8):2796-802. PubMed ID: 9704732
[TBL] [Abstract][Full Text] [Related]
37. Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma.
Horning SJ; Negrin RS; Chao JC; Long GD; Hoppe RT; Blume KG
J Clin Oncol; 1994 Dec; 12(12):2552-8. PubMed ID: 7989928
[TBL] [Abstract][Full Text] [Related]
38. Influence of ex vivo purging with CliniMACS CD34(+) selection on outcome after autologous stem cell transplantation in non-Hodgkin lymphoma.
Yahng SA; Yoon JH; Shin SH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Kim DW; Lee JW; Min WS; Park CW; Kim Y; Cho SG
Br J Haematol; 2014 Feb; 164(4):555-64. PubMed ID: 24266323
[TBL] [Abstract][Full Text] [Related]
39. Autologous bone marrow transplantation for acute myeloid leukemia in remission or first relapse using monoclonal antibody-purged marrow: results of phase II studies with long-term follow-up.
Ball ED; Wilson J; Phelps V; Neudorf S
Bone Marrow Transplant; 2000 Apr; 25(8):823-9. PubMed ID: 10808202
[TBL] [Abstract][Full Text] [Related]
40. Retrospective evaluation of autologous bone marrow transplantation vs allogeneic bone marrow transplantation from an HLA identical related donor in acute myelocytic leukemia. A study of the European Cooperative Group for Blood and Marrow Transplantation (EBMT).
Gorin NC; Labopin M; Fouillard L; Meloni G; Frassoni F; Iriondo A; Brunet Mauri S; Goldstone AH; Harousseau JL; Reiffers J; Esperou-Bourdeau H; Gluckman E
Bone Marrow Transplant; 1996 Jul; 18(1):111-7. PubMed ID: 8832003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
